Influence of different preservation solutions and placing time on survival rate of umbilical cord-derived mesenchymal stem cells

doi:10.3969/j.issn.2095-4344.2015.23.010

Abstract

Abstract:

BACKGROUND: The relationship between placing time after stem cell preparation and cell survival is the basis of safety and effectiveness for the clinical application.
OBJECTIVE: To observe effects of different preservation solutions and different storage time on survival rate of umbilical cord-derived mesenchymal stem cells, and to provide important evidence for identifying effectiveness of stem cells.
METHODS: Umbilical cord-derived mesenchymal stem cells were selected to prepare stem cell preparation, which was preserved in physiological saline, medium, medium+physiological saline, physiological saline containing epidermal growth factor, and medium containing low molecular heparin calcium suspension. Cold closet was selected for imitating cellular transport conditions. Samples were obtained at 0, 6, 12, 18, 24, 30, 36, 42 and 48 hours. Total cell number and cell survival rate were detected.
RESULTS AND CONCLUSION: The difference in cell number and survival rate was not great within 24 hours in each group. Twenty-four hours later, total cell number and survival rate were better in the medium and medium containing low molecular heparin calcium groups than in the physiological saline containing epidermal growth factor, physiological saline, and medium+physiological saline groups. These findings suggest that after stem cell preparation, the cell survival rate can reach more than 90% within 24 hours under refrigerated transport conditions. Nutritional ingredients and proper pH value of preservation solution can make the cell survival rate increased greatly.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

CLC Number:

R394.2

Li Zhi-gang, Ben Liang, Han Yu, Bi Wei-wei. Influence of different preservation solutions and placing time on survival rate of umbilical cord-derived mesenchymal stem cells[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(23): 3664-3668.

Figures/Tables 3

References

[1] Gamie Z, MacFarlane RJ, Tomkinson A,et al. Skeletal tissue engineering using mesenchymal or embryonic stem cells: clinical and experimental data. Expert Opin Biol Ther. 2014; 14(11):1611-1639.

[2] Wang G, Li Y, Wang Y, et al. Roles of the co-culture of human umbilical cord Wharton's jelly-derived mesenchymal stem cells with rat pancreatic cells in the treatment of rats with diabetes mellitus. Exp Ther Med. 2014;8(5):1389-1396.

[3] Woodworth TG, Furst DE. Safety and feasibility of umbilical cord mesenchymal stem cells in treatment-refractory systemic lupus erythematosus nephritis: time for a double-blind placebo-controlled trial to determine efficacy. Arthritis Res Ther. 2014;16(4):113.

[4] Wen Y, Gu W, Cui J,et al. Platelet-rich plasma enhanced umbilical cord mesenchymal stem cells-based bone tissue regeneration. Arch Oral Biol. 2014;59(11):1146-1154.

[5] Wakao S, Matsuse D, Dezawa M. Mesenchymal stem cells as a source of schwann cells: their anticipated use in peripheral nerve regeneration. Cells Tissues Organs. 2014;200(1):31-41.

[6] Cui B, Li E, Yang B, et al. Human umbilical cord blood-derived mesenchymal stem cell transplantation for the treatment of spinal cord injury. Exp Ther Med. 2014;7(5):1233-1236.

[7] Xiong N, Zhang Z, Huang J,et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson's disease. Gene Ther. 2011;18(4): 394-402.

[8] Wang X, Hu H, Hua R,et al. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy. 2015;17(2): 224-231.

[9] Lee HJ, Lee JK, Lee H, et al. The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer's disease. Neurosci Lett. 2010;481(1):30-35.

[10] El-Jawhari JJ, El-Sherbiny YM, Jones EA,et al. Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM. 2014; 107(7):505-514.

[11] Xue HL, Zeng WZ, Wu XL, et al. Clinical therapeutic effects of human umbilical cord-derived mesenchymal stem cells transplantation in the treatment of end-stage liver disease. Transplant Proc. 2015;47(2):412-418.

[12] Santos Nascimento D, Mosqueira D, Sousa LM,et al. Human umbilical cord tissue-derived mesenchymal stromal cells attenuate remodeling after myocardial infarction by proangiogenic, antiapoptotic, and endogenous cell-activation mechanisms. Stem Cell Res Ther. 2014;5(1):5.

[13] Chao YH, Wu HP, Wu KH, et al. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis. PLoS One. 2014;9(10):e110338.

[14] Wu KH, Tsai C, Wu HP, et al. Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplant. 2013;22(11):2041-2051.

[15] Auletta JJ, Eid SK, Wuttisarnwattana P,et al. Human mesenchymal stromal cells attenuate graft-versus-host disease and maintain graft-versus-leukemia activity following experimental allogeneic bone marrow transplantation. Stem Cells. 2015;33(2):601-614.

[16] 《中国组织工程研究与临床康复》杂志社学术部. 《干细胞临床转化指南》:干细胞临床应用标准与规则[J].中国组织工程研究与临床康复,2010,14(36):6798-6799.

[17] 国家食品药品监督管理局.《人体细胞治疗研究和制剂质量控制技术指导原则》[EB/OL]. http://www.sda.gov.cn/ WS01/ CL0237/15709.html, 2003-03-20

[18] Bosse R, Singhofer-Wowra M, Rosenthal F, et al. Good manufacturing practice production of human stem cells for somatic cell and gene therapy. Stem Cells. 1997;15 Suppl 1: 275-280.

[19] 毕薇薇,郭立斌,李志刚.人脐带源间充质干细胞的培养及生物学性状[J].中国现代医学杂志,2009,19(10):1511-1513.

[20] Eftekhar-Vaghefi SH, Zahmatkesh L, Salehinejad P, et al. Evaluation of neurogenic potential of human umbilical cord mesenchymal cells; a time- and concentration-dependent manner. Iran Biomed J. 2015;19(2):82-90.

[21] Frausin S, Viventi S, Verga Falzacappa L, et al. Wharton's jelly derived mesenchymal stromal cells: Biological properties, induction of neuronal phenotype and current applications in neurodegeneration research. Acta Histochem. 2015 Mar 3. [Epub ahead of print]

[22] Coskun H, Can A. The assessment of the in vivo to in vitro cellular transition of human umbilical cord multipotent stromal cells. Placenta. 2015;36(2):232-239.

[23] Maleki M, Ghanbarvand F, Reza Behvarz M, et al. Comparison of mesenchymal stem cell markers in multiple human adult stem cells. Int J Stem Cells. 2014;7(2):118-126.

[24] Shaer A, Azarpira N, Aghdaie MH, et al. Isolation and characterization of Human Mesenchymal Stromal Cells Derived from Placental Decidua Basalis; Umbilical cord Wharton's Jelly and Amniotic Membrane. Pak J Med Sci. 2014;30(5):1022-1026.

[25] Mueller AA, Forraz N, Gueven S, et al. Osteoblastic differentiation of Wharton jelly biopsy specimens and their mesenchymal stromal cells after serum-free culture. Plast Reconstr Surg. 2014;134(1):59e-69e.

[26] Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195-202.

[27] 张可华,纳涛,刘静,等.建立间充质干细胞制剂质量控制评价体系[C].南宁:2013年中国药学大会暨第十三届中国药师周论文集, 2013-11-02.

[28] 孙瑞婷,陈瑶瑶,王华,等. 脐带来源间充质干细胞的制备及其质量检定[J].中国医药生物技术,2013,8(6):401-407.